Overproduction of IL-6 and dysregulation of the IL-6 receptor (IL-6R) have been implicated in the pathogenesis of inflammatory disease, autoimmune disease, and cancer, driving the development of multiple drugs to block the IL-6 signaling pathway (2, 3). This evidence concerns the gene IL6 and cancer.